Advertisement

Introduction of metformin for gestational diabetes mellitus in clinical practice: has it had an impact?

Published:November 24, 2011DOI:https://doi.org/10.1016/j.ejogrb.2011.11.018

      Abstract

      Objective

      The aim of the study was to compare maternal and neonatal outcomes in women with gestational diabetes mellitus (GDM) treated with metformin in addition to the dietary and lifestyle advice versus those treated traditionally with dietary and lifestyle advice only.

      Study design

      A retrospective study of singleton pregnancies in women with GDM delivered between January 2008 to June 2010 (n = 592) at the Jessop Wing, Royal Hallamshre Hospital, UK. Introduction of metformin in August 2008 led to two comparable groups, those women receiving metformin, lifestyle advice (including dietary advice) ± supplementary insulin and those women receiving lifestyle advice (including dietary advice) ± supplementary insulin. Two hundred and ninety three women were treated with metformin and lifestyle advice and remaining 299 with lifestyle advice only. Supplementary insulin was used in both the groups if needed. Outcomes were analyzed using the chi-squared and t-tests.

      Results

      There were no significant differences in baseline maternal characteristics between the two groups. Metformin was tolerated throughout the pregnancy by 90% of the women in the metformin + lifestyle advice group. Supplementary insulin was required by 21% in the metformin + lifestyle advice group compared to 37% in the lifestyle advice group (OR 0.46; 95% CI 0.32–0.66). Women in the metformin group had a significantly lower incidence of macrosomia (birth weight > 4 kg) (8.2% vs. 14.3% (OR 0.56; 95% CI 0.33–0.99)), as well as birth weight >90th centile (14.8% vs. 23.7% (OR 0.56; 95% CI 0.37–0.85)). There were no significant differences in maternal outcome measures between the groups. No serious maternal or neonatal adverse events were observed with the use of metformin.

      Conclusion

      Metformin is safe and effective in the treatment of GDM in our experience. It is well tolerated and reduces the requirement for supplementary insulin. Women treated with metformin had a significantly lower incidence of macrosomic and large for gestational age neonates as well as a reduced caesarean section rate.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • World Health Organization and Department of Non-communicable Disease Surveillance
        Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus.
        World Health Organization, Geneva1999
      1. Diabetes in the UK 2010: Key statistics on diabetes.
        Diabetes, UK2010
        • Kjos S.L.
        • Buchanan T.A.
        Gestational diabetes mellitus.
        N Engl J Med. 1999; 341: 1749-1756
        • Xiong X.
        • Saunders L.D.
        • Wang F.L.
        • Demianczuk N.N.
        Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes.
        Int J Gynaecol Obstet. 2001; 75: 221-228
        • Yogev Y.
        • Xenakis E.M.
        • Langer O.
        The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control.
        Am J Obstet Gynecol. 2004; 191: 1655-1660
        • Crowther C.A.
        • Hiller J.E.
        • Moss J.R.
        • et al.
        Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.
        N Engl J Med. 2005; 352: 2477-2486
        • Landon M.B.
        • Spong C.Y.
        • Thom E.
        • et al.
        A multicenter, randomized trial of treatment for mild gestational diabetes.
        N Engl J Med. 2009; 361: 1339-1348
        • Rowan J.A.
        • Hague W.M.
        • Gao W.
        • Battin M.R.
        • Moore M.P.
        • MiG Trial Investigators
        Metformin versus insulin for the treatment of gestational diabetes.
        N Engl J Med. 2008; 358: 2003-2015
        • Dhulkotia J.S.
        • Ola B.
        • Fraser R.
        • Farrell T.
        Oral hypoglycemic agents vs. insulin in management of gestational diabetes: a systematic review and meta-analysis.
        Am J Obstet Gynecol. 2010; 203: 457-459
        • Moore L.E.
        • Clokey D.
        • Rappaport V.J.
        • Curet L.B.
        Metformin compared with glyburide in gestational diabetes: a randomized controlled trial.
        Obstet Gynecol. 2010; 115: 55-59
        • DeFronzo R.A.
        • Simonson D.C.
        Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.
        Diabetes Care. 1984; 7: 72-80
        • Stumvoll M.
        • Nurjhan N.
        • Perriello G.
        • Dailey G.
        • Gerich J.E.
        Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.
        N Engl J Med. 1995; 333: 588-589
        • Yogev Y.
        • Langer O.
        The use of anti-hyperglycaemic and hypoglycaemic agents in pregnancy.
        Fetal Matern Med Rev. 2004; 15: 133-143
        • Glueck C.J.
        • Goldenberg N.
        • Wang P.
        • Loftspring M.
        • Sherman A.
        Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone, and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy.
        Hum Reprod. 2004; 19: 510-521
        • Rowan J.A.
        Gestational diabetes—complications, management, outcomes.
        Reprod Fertil Dev. 2010; 22: 7
        • National Institute for Health and Clinical Excellence
        NICE clinical guideline CG63. Diabetes in pregnancy. Management of diabetes and its complications from pre-conception to the postnatal period.
        NICE, London2008
        • Boney C.M.
        • Verma A.
        • Tucker R.
        • Vohr B.R.
        Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus.
        Pediatrics. 2005; 115: 290-296
        • Dietz W.H.
        Overweight in childhood and adolescence.
        N Engl J Med. 2004; 350: 855-857
        • Balani J.
        • Hyer S.L.
        • Rodin D.A.
        • Shehata H.
        Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study.
        Diabet Med. 2009; 26: 798-802
        • Boulet S.L.
        • Alexander G.R.
        • Hamisu M.S.
        • Pass M.A.
        Macrosomic births in the United States: determinants, outcomes and proposed grades of risk.
        Am J Obstet Gynecol. 2003; 188: 1372-1378
        • Raio L.
        • Ghezzi F.
        • Di Naro E.
        • et al.
        Perinatal outcome of foetuses with a birth weight greater than 4500 g: an analysis of 3356 cases.
        Eur J Obstet Gynecol Reprod Biol. 2003; 109: 160-165
        • Charles B.
        • Norris R.
        • Xiao X.
        • Hague W.
        Population pharmacokinetics of metformin in late pregnancy.
        Ther Drug Monit. 2006; 28: 67-72